Glenmark Pharmaceuticals Limited (BOM:532296)
India
· Delayed Price · Currency is INR 1,349.00
-20.40 (-1.49%)
At close: Feb 20, 2025
Glenmark Pharmaceuticals Statistics
Total Valuation
BOM:532296 has a market cap or net worth of INR 367.07 billion. The enterprise value is 366.67 billion.
| Market Cap | 367.07B |
| Enterprise Value | 366.67B |
Important Dates
The last earnings date was Friday, February 7, 2025.
| Earnings Date | Feb 7, 2025 |
| Ex-Dividend Date | Sep 13, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.03% |
| Shares Change (QoQ) | +99.98% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 142.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 5.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -208.53 |
| EV / Sales | 2.63 |
| EV / EBITDA | 11.59 |
| EV / EBIT | 14.02 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 0.56 |
| Debt / FCF | n/a |
| Interest Coverage | 9.05 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 13.00% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 9.31M |
| Profits Per Employee | -117,309 |
| Employee Count | 14,989 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +50.91% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +50.91% |
| 50-Day Moving Average | 1,494.87 |
| 200-Day Moving Average | 1,484.70 |
| Relative Strength Index (RSI) | 32.84 |
| Average Volume (20 Days) | 50,068 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BOM:532296 had revenue of INR 139.61 billion and -1.76 billion in losses. Loss per share was -6.23.
| Revenue | 139.61B |
| Gross Profit | 95.35B |
| Operating Income | 26.15B |
| Pretax Income | 19.22B |
| Net Income | -1.76B |
| EBITDA | 30.69B |
| EBIT | 26.15B |
| Loss Per Share | -6.23 |
Balance Sheet
The company has 18.20 billion in cash and 17.81 billion in debt, giving a net cash position of 393.95 million.
| Cash & Cash Equivalents | 18.20B |
| Total Debt | 17.81B |
| Net Cash | 393.95M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 84.45B |
| Book Value Per Share | 598.47 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 68.30%, with operating and profit margins of 18.73% and -1.26%.
| Gross Margin | 68.30% |
| Operating Margin | 18.73% |
| Pretax Margin | 13.77% |
| Profit Margin | -1.26% |
| EBITDA Margin | 21.98% |
| EBIT Margin | 18.73% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 2.50, which amounts to a dividend yield of 0.19%.
| Dividend Per Share | 2.50 |
| Dividend Yield | 0.19% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.03% |
| Shareholder Yield | 0.21% |
| Earnings Yield | -0.48% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on September 10, 2007. It was a forward split with a ratio of 2.
| Last Split Date | Sep 10, 2007 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |